Novavax is a vaccine company that for decades never brought a vaccine to market. Before the pandemic, they were on the verge of bankruptcy. WSJ's Gregory Zuckerman and Novavax's Dr. Gregory Glenn explain how the company's fortunes are now changing thanks to its Covid-19 vaccine, which is delivering promising results.